TRLV Trulieve Cannabis Corp.
Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Trulieve Cannabis (NYSE: TRLV)
›
Trulieve Cannabis (NYSE: TRLV) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 5,000 employees.
The shares were at 10.90 USD on 13 November 2026, up 22.5% over 52 weeks. Its 52-week range is 4.616 USD to 13.28 USD: the price is 17.9% below the high and 136.1% above the low.
Its market capitalisation is 1.86B USD.
Trulieve Cannabis reports return on equity of -10.0%, an operating margin of 12.2% and revenue down 20.1% year over year.
Its debt exceeds its cash by 255.57M USD, a debt-to-equity ratio of 0.49. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 18.32 USD is 68.1% above the current price. The next earnings report is expected on 25 February 2027.